+高级检索
首页 > 过刊浏览>2017年第27卷第11期 >100-105. DOI:10.3969.j.issn.1671-7856.2017.11.021
PDF HTML阅读 XML下载 导出引用 引用提醒
异质性胞核核糖核蛋白K与肿瘤研究的最新进展
作者:
基金项目:

协和青年科研基金（编号：3332016078）；中央级公益性科研院所基本业务费（编号：2016RC310012）。


Recent progress in research of heterogeneous nuclear ribonucleoprotein K related with tumor pathogenesis and progression
Author:
  • HUANG Hao

    HUANG Hao

    Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences(CAMS) & Comparative Medicine Center, Peking Union Medical College(PUMC);Key Laboratory of Human Diseases Comparative Medicine, National Health and Family Planning Commission of P. R. C, Beijing 100021, China
    在期刊界中查找
    在百度中查找
    在本站中查找
  • YANG Xing-jiu

    YANG Xing-jiu

    Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences(CAMS) & Comparative Medicine Center, Peking Union Medical College(PUMC);Key Laboratory of Human Diseases Comparative Medicine, National Health and Family Planning Commission of P. R. C, Beijing 100021, China
    在期刊界中查找
    在百度中查找
    在本站中查找
  • Li Meng-yuan

    Li Meng-yuan

    Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences(CAMS) & Comparative Medicine Center, Peking Union Medical College(PUMC);Key Laboratory of Human Diseases Comparative Medicine, National Health and Family Planning Commission of P. R. C, Beijing 100021, China
    在期刊界中查找
    在百度中查找
    在本站中查找
  • ZHU Rui-min

    ZHU Rui-min

    Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences(CAMS) & Comparative Medicine Center, Peking Union Medical College(PUMC);Key Laboratory of Human Diseases Comparative Medicine, National Health and Family Planning Commission of P. R. C, Beijing 100021, China
    在期刊界中查找
    在百度中查找
    在本站中查找
  • GAO Ran

    GAO Ran

    Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences(CAMS) & Comparative Medicine Center, Peking Union Medical College(PUMC);Key Laboratory of Human Diseases Comparative Medicine, National Health and Family Planning Commission of P. R. C, Beijing 100021, China
    在期刊界中查找
    在百度中查找
    在本站中查找
  • 摘要
    • | |
  • 访问统计
    • |
  • 参考文献 [48]
    • | | | |
  • 文章评论
    摘要:

    近几十年来，癌基因和抑癌基因一直是肿瘤生物学中的一个重要分类，然而对于一些基因却很难将其归类。异质性胞核核糖核蛋白K（heterogeneous nuclear ribonucleoprotein K，HNRNPK）是一个核酸结合蛋白，参与了基因表达调控、信号转导等很多细胞进程。近些年发现HNRNPK在多种肿瘤中过表达，且其过表达与患者的预后呈负相关，提示其可能在这些肿瘤中发挥癌基因的功能。然而，在急性髓系白血病（acute myeloid leukemia，AML）的研究报道中发现HNRNPK可能扮演抑癌基因的角色。因此，本文对HNRNPK在肿瘤发生发展中的分子功能及作用机制的最新进展进行综述。

    Abstract:

    Over the past few decades, the classification of oncogenes or tumor suppressor genes has been an important topic in cancer biology. However, it is difficult to classify some genes. Heterogeneous nuclear ribonucleoprotein K (HNRNPK) is a nucleic acid-binding protein, which is involved in the regulation of gene expression, signal transduction and many other cellular processes. In recent years, it has been found that HNRNPK is overexpressed in many types of tumors, and its overexpression is negatively correlated with the prognosis of patients, suggesting that HNRNPK may play a role as an oncogene in tumorigenesis. In contrast, however, HNRNPK has also been considered as a tumor suppressor gene in acute myeloid leukemia (AML). Therefore, in this article we summarize and discuss the recent progress in the molecular functions and regulatory mechanisms of HNRNPK in tumorigenesis and progression.

    参考文献
    [1] Mishra A, Brat DJ, Verma M. P53 tumor suppression network in cancer epigenetics [J]. Methods Mol Biol, 2015, 1238: 597-605.
    [2] Carpenter B, McKay M, Dundas SR, et al. Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer [J]. Br J Cancer, 2006, 95(7): 921-927.
    [3] Chen LC, Chung IC, Hsueh C, et al. The antiapoptotic protein, FLIP, is regulated by heterogeneous nuclear ribonucleoprotein K and correlates with poor overall survival of nasopharyngeal carcinoma patients [J]. Cell Death Differ, 2010, 17(9): 1463-1473.
    [4] Ciarlo M, Benelli R, Barbieri O, et al. Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/β-catenin signaling in prostate cancer cells [J]. Int J Cancer, 2012, 131(3): 582-590.
    [5] Wen F, Shen A, Shanas R, et al. Higher expression of the heterogeneous nuclear ribonucleoprotein K in melanoma [J]. Ann Surg Oncol, 2010, 17(10): 2619-2627.
    [6] Wu CS, Chang KP, Chen LC, et al. Heterogeneous ribonucleoprotein K and thymidine phosphorylase are independent prognostic and therapeutic markers for oral squamous cell carcinoma [J]. Oral Oncol, 2012, 48(6): 516-522.
    [7] Yang R, Zeng Y, Xu H, et al. Heterogeneous nuclear ribonucleoprotein K is overexpressed and associated with poor prognosis in gastric cancer [J]. Oncol Rep, 2016, 36(2): 929-935.
    [8] Gallardo M, Lee HJ, Zhang X, et al. hnRNP K is a haploinsufficient tumor suppressor that regulates proliferation and differentiation programs in hematologic malignancies [J]. Cancer Cell, 2015, 28(4): 486-499.
    [9] Siomi H, Matunis MJ, Michael WM, et al. The pre-mRNA binding K protein contains a novel evolutionarily conserved motif [J]. Nucleic Acids Res, 1993, 21(5): 1193-1198.
    [10] Chkheidze AN, Liebhaber SA. A novel set of nuclear localization signals determine distributions of the αCP RNA-binding proteins [J]. Mol Cell Biol, 2003, 23(23): 8405-8415.
    [11] Barboro P, Ferrari N, Balbi C. Emerging roles of heterogeneous nuclear ribonucleoprotein K (hnRNP K) in cancer progression [J]. Cancer Lett, 2014, 352(2): 152-159.
    [12] Choi HS, Hwang CK, Song KY, et al. Poly(C)-binding proteins as transcriptional regulators of gene expression [J]. Biochem Biophys Res Commun, 2009, 380(3): 431-436.
    [13] Tomonaga T, Levens D. Heterogeneous nuclear ribonucleoprotein K is a DNA-binding transactivator [J]. J Biol Chem, 1995, 270(9): 4875-4881.
    [14] Uribe DJ, Guo K, Shin YJ, et al. Heterogeneous nuclear ribonucleoprotein K and nucleolin as transcriptional activators of the vascular endothelial growth factor promoter through interaction with secondary DNA structures [J]. Biochemistry, 2011, 50(18): 3796-3806.
    [15] Moumen A, Masterson P, O’Connor MJ, et al. hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage [J]. Cell, 2005, 123(6): 1065-1078.
    [16] Enge M, Bao W, Hedström E, et al. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53 [J]. Cancer Cell, 2009, 15(3): 171-183.
    [17] Shnyreva M, Schullery DS, Suzuki H, et al. Interaction of two multifunctional proteins. Heterogeneous nuclear ribonucleoprotein K and Y-box-binding protein [J]. J Biol Chem, 2000, 275(20): 15498-15503.
    [18] Revil T, Pelletier J, Toutant J, et al. Heterogeneous nuclear ribonucleoprotein K represses the production of pro-apoptotic Bcl-xS splice isoform [J]. J Biol Chem, 2009, 284(32): 21458-21467.
    [19] Cyphert TJ, Suchanek AL, Griffith BN, et al. Starvation actively inhibits splicing of glucose-6-phosphate dehydrogenase mRNA via a bifunctional ESE/ESS element bound by hnRNP K [J]. Biochim Biophys Acta, 2013, 1829(9): 905-915.
    [20] Bomsztyk K, Van Seuningen I, Suzuki H, et al. Diverse molecular interactions of the hnRNP K protein [J]. FEBS Lett, 1997, 403(2): 113-115.
    [21] Lynch M, Chen L, Ravitz MJ, et al. hnRNP K binds a core polypyrimidine element in the eukaryotic translation initiation factor 4E (eIF4E) promoter, and its regulation of eIF4E contributes to neoplastic transformation [J]. Mol Cell Biol, 2005, 25(15): 6436-6453.
    [22] Yano M, Okano HJ,Okano H. Involvement of Hu and heterogeneous nuclear ribonucleoprotein K in neuronal differentiation through p21 mRNA post-transcriptional regulation [J]. J Biol Chem, 2005, 280(13): 12690-12699.
    [23] Naarmann IS, Harnisch C, Flach N, et al. mRNA silencing in human erythroid cell maturation: heterogeneous nuclear ribonucleoprotein K controls the expression of its regulator c-Src [J]. J Biol Chem, 2008, 283(26): 18461-18472.
    [24] Chang YI, Hsu SC, Chau GY, et al. Identification of the methylation preference region in heterogeneous nuclear ribonucleoprotein K by protein arginine methyltransferase 1 and its implication in regulating nuclear/cytoplasmic distribution [J]. Biochem Biophys Res Commun, 2011, 404(3): 865-869.
    [25] Ostareck-Lederer A, Ostareck DH, Rucknagel KP, et al. Asymmetric arginine dimethylation of heterogeneous nuclear ribonucleoprotein K by protein-arginine methyltransferase 1 inhibits its interaction with c-Src [J]. J Biol Chem, 2006, 281(16): 11115-11125.
    [26] Chen Y, Zhou X, Liu N, et al. Arginine methylation of hnRNP K enhances p53 transcriptional activity [J]. FEBS Lett, 2008, 582(12): 1761-1765.
    [27] Pelisch F, Pozzi B, Risso G, et al. DNA damage-induced heterogeneous nuclear ribonucleoprotein K SUMOylation regulates p53 transcriptional activation [J]. J Biol Chem, 2012, 287(36): 30789-30799.
    [28] Lee SW, Lee MH, Park JH, et al. SUMOylation of hnRNP-K is required for p53-mediated cell-cycle arrest in response to DNA damage [J]. EMBO J, 2012, 31(23): 4441-4452.
    [29] Habelhah H, Shah K, Huang L, et al. Identification of new JNK substrate using ATP pocket mutant JNK and a corresponding ATP analogue [J]. J Biol Chem, 2001, 276(21): 18090-18095.
    [30] The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia [J]. N Engl J Med, 2013, 368(22): 2059-2074.
    [31] Ostareck-Lederer A, Ostareck DH, Cans C, et al. c-Src-mediated phosphorylation of hnRNP K drives translational activation of specifically silenced mRNAs [J]. Mol Cell Biol, 2002, 22(13): 4535-4543.
    [32] Takimoto M, Tomonaga T, Matunis M, et al. Specific binding of heterogeneous ribonucleoprotein particle protein K to the human c-myc promoter, in vitro [J]. J Biol Chem, 1993, 268(24): 18249-18258.
    [33] Mandal M, Vadlamudi R, Nguyen D, et al. Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function [J]. J Biol Chem, 2001, 276(13): 9699-9704.
    [34] Nagano K, Masters JR, Akpan A, et al. Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and Ⅱ interferons [J]. Oncogene, 2004, 23(9): 1693-1703.
    [35] Hong X, Song R, Song H, et al. PTEN antagonises Tcl1/hnRNPK-mediated G6PD pre-mRNA splicing which contributes to hepatocarcinogenesis [J]. Gut, 2014, 63(10): 1635-1647.
    [36] Inoue A, Sawata SY, Taira K, et al. Loss-of-function screening by randomized intracellular antibodies: identification of hnRNP-K as a potential target for metastasis [J]. Proc Natl Acad Sci U S A, 2007, 104(21): 8983-8988.
    [37] Gao R, Yu Y, Inoue A, et al. Heterogeneous nuclear ribonucleoprotein K (hnRNP-K) promotes tumor metastasis by induction of genes involved in extracellular matrix, cell movement, and angiogenesis [J]. J Biol Chem, 2013, 288(21): 15046-15056.
    [38] Strozynski J, Heim J, Bunbanjerdsuk S, et al. Proteomic identification of the heterogeneous nuclear ribonucleoprotein K as irradiation responsive protein related to migration [J]. J Proteomics, 2015, 113: 154-161.
    [39] Otoshi T, Tanaka T, Morimoto K, et al. Cytoplasmic accumulation of heterogeneous nuclear ribonucleoprotein K strongly promotes tumor invasion in renal cell carcinoma cells [J]. PLoS One, 2015, 10(12): e0145769.
    [40] 陈艳, 李为民, 张尚福. hnRNP K在肺癌组织中的表达 [J]. 中国肺癌杂志, 2008, 11(2): 241-245.
    [41] Yang JH, Chiou YY, Fu SL, et al. Arginine methylation of hnRNPK negatively modulates apoptosis upon DNA damage through local regulation of phosphorylation [J]. Nucleic Acids Res, 2014, 42(15): 9908-9924.
    [42] Zhang Z, Zhou C, Chang Y, et al. Long non-coding RNA CASC11 interacts with hnRNP-K and activates the WNT/β-catenin pathway to promote growth and metastasis in colorectal cancer [J]. Cancer Lett, 2016, 376(1): 62-73.
    [43] Eder S, Lamkowski A, Priller M, et al. Radiosensitization and downregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K) upon inhibition of mitogen/extracellular signal-regulated kinase (MEK) in malignant melanoma cells [J]. Oncotarget, 2015, 6(19): 17178-17191.
    [44] Eder S, Arndt A, Lamkowski A, et al. Baseline MAPK signaling activity confers intrinsic radioresistance to KRAS-mutant colorectal carcinoma cells by rapid upregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K) [J]. Cancer Lett, 2017, 385: 160-167.
    [45] Zhang J, Liu X, Lin Y, et al. HnRNP K contributes to drug resistance in acute myeloid leukemia through the regulation of autophagy [J]. Exp Hematol, 2016, 44(9): 850-856.
    [46] Gao X, Feng J, He Y, et al. hnRNPK inhibits GSK3β Ser9 phosphorylation, thereby stabilizing c-FLIP and contributes to TRAIL resistance in H1299 lung adenocarcinoma cells [J]. Sci Rep, 2016, 6: 22999.
    [47] Gao R, Shah N, Lee JS, et al. Withanone-rich combination of Ashwagandha withanolides restricts metastasis and angiogenesis through hnRNP-K [J]. Mol Cancer Ther, 2014, 13(12): 2930-2940.
    [48] Zhang L, Feng J, Kong S, et al. Nujiangexathone A, a novel compound from Garcinia nujiangensis, suppresses cervical cancer growth by targeting hnRNPK [J]. Cancer Lett, 2016, 380(2): 447-456.
    相似文献
    引证文献
    网友评论
    网友评论
    分享到微博
    发 布
引用本文

黄昊,杨星九,李梦媛,朱瑞敏,高苒.异质性胞核核糖核蛋白K与肿瘤研究的最新进展[J].中国比较医学杂志,2017,27(11):100~105.

复制
分享
文章指标
  • 点击次数:2470
  • 下载次数: 3098
  • HTML阅读次数: 0
  • 引用次数: 0
历史
  • 收稿日期:2017-01-09
  • 在线发布日期: 2017-11-28
您是第8912996 位访问者
版权所有:中国比较医学杂志 主管单位：中国科学技术协会 主办单位：中国实验动物学会 中国医学科学院医学实验动物研究所
地址：北京市朝阳区潘家园南里5号 邮 编 ：100021 电话：010-67779337 E-mail:bjb@cnilas.org
技术支持：北京勤云科技发展有限公司
防诈骗提示！请勿点击不明链接或添加个人微信。编辑部所有邮箱后缀均为@cnilas.org
关闭